content: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 16, 2002
                                                          ------------------
  
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
  
             Delaware                      000-14879               222322400
  --------------------------------------------------------------------------------
   (State or Other Jurisdiction    (Commission File Number)      (IRS Employer
         of Incorporation)                                     Identification No.)
  
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ              08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                             (Zip Code)
  
  
  
                                   (609) 750-8200
                  ------------------------------------------------
                (Registrant's telephone number, including area code)
  
  
                 600 College Road East, CN 5308, Princeton, NJ 08540
             ------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  <PAGE>
  
  
           Item 5.           Other Events.
  
       On September 16, 2002,  Cytogen  Corporation (the "Company") issued a press
  release reporting the internal restructuring of the Company's AxCell Biosciences
  subsidiary.
  
       On  September  17,  2002,  the Company  issued a joint press  release  with
  Matritech  Inc.  announcing  an agreement in principle to enter into a five year
  agreement  for  the  Company  to be  the  sole  United  States  distributor  for
  Matritech's  NMP22(R)  BladderChek(TM)  test.  Such  arrangement  is pending the
  approval and execution of a final agreement by both parties.
  
       Each such press  release is  attached  hereto as Exhibit  99.1 and  Exhibit
  99.2, respectively,  and each is incorporated herein by reference. The foregoing
  description of each such press release is qualified in its entirety by reference
  to each such respective document.
  
           Item 7.  Financial Statements, Pro Forma Financial Information
  and Exhibits.
  
           (c) Exhibits.
  
            Exhibit No.      Description
            -----------      -----------
               99.1          Press release of the Company dated September 16, 2002
               99.2          Press release of the Company dated September 17, 2002
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
  
                                           Cytogen Corporation
  
  
  
                                           By: /s/ Lawrence R. Hoffman
                                               -----------------------------------
                                                Lawrence R. Hoffman,
                                                 Chief Financial Officer
  
  
  Date:  September 17, 2002
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "hd_form8-k091602.txt", "description": "CYTOGEN CORP. FORM 8-K 091602", "secsgml_size_bytes": 3462}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "02765946"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 16, 2002
                                                          ------------------
  
                                 CYTOGEN CORPORATION
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                      000-14879               222322400
  --------------------------------------------------------------------------------
   (State or Other Jurisdiction    (Commission File Number)      (IRS Employer
         of Incorporation)                                     Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ              08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                             (Zip Code)
  
                                   (609) 750-8200
                  ------------------------------------------------
                (Registrant's telephone number, including area code)
  
                 600 College Road East, CN 5308, Princeton, NJ 08540
             ------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  Item 5.           Other Events.
  
       On September 16, 2002,  Cytogen  Corporation (the "Company") issued a press
  release reporting the internal restructuring of the Company's AxCell Biosciences
  subsidiary.
  
       On  September  17,  2002,  the Company  issued a joint press  release  with
  Matritech  Inc.  announcing  an agreement in principle to enter into a five year
  agreement  for  the  Company  to be  the  sole  United  States  distributor  for
  Matritech's  NMP22(R)  BladderChek(TM)  test.  Such  arrangement  is pending the
  approval and execution of a final agreement by both parties.
  
       Each such press  release is  attached  hereto as Exhibit  99.1 and  Exhibit
  99.2, respectively,  and each is incorporated herein by reference. The foregoing
  description of each such press release is qualified in its entirety by reference
  to each such respective document.
  
           Item 7.  Financial Statements, Pro Forma Financial Information
  and Exhibits.
  
           (c) Exhibits.
  
            Exhibit No.      Description
            -----------      -----------
               99.1          Press release of the Company dated September 16, 2002
               99.2          Press release of the Company dated September 17, 2002
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                           Cytogen Corporation
  
                                           By: /s/ Lawrence R. Hoffman
                                               -----------------------------------
                                                Lawrence R. Hoffman,
                                                 Chief Financial Officer
  
  Date:  September 17, 2002